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INTRODUCTION
NIH/3T3 (ATCC® CRL-1658) cells are adherent embryonic
mouse fibroblast cells, used as a model in in vitro
experiments due to their high survivability and short transition
through the cell cycle.
Integrins are heterodimeric transmembrane proteins found in 
many cell types, including NIH/3T3 cells, and are involved in 
extracellular matrix adhesion and cell to cell signaling. They 
are composed of alpha (𝛼𝛼) and beta (𝛽𝛽) subunits that can 
form 24 different heterodimer combinations, each being 
characterized by their individual ligand binding properties. For 
example, 𝛼𝛼2𝛽𝛽1 binds to collagen,  𝛼𝛼3𝛽𝛽1 binds to laminin, and 
𝛼𝛼4𝛽𝛽1 binds to fibronectin. In other cell lines, researchers 
have seen that upregulation of an integrin protein results in 
the down regulation of another, also known as an integrin 
switch. NIH/3T3 cells treated with ascorbic acid may lead to 
an integrin switch in genes involved in cell differentiation and 
proliferation. In this experiment, we explored the effects of 
high ascorbic acid treatment on NIH/3T3 cells, and the 
possibility of a resulting integrin switch. 
High concentration of ascorbic acid is becoming a common 
cancer treatment for some individuals, and NIH/3T3 cells 
may serve as a model to gain a better understanding of how 
integrin expression on cancer-associated fibroblasts may 
play a role in deleterious cancers, such as breast cancer. 
Still, the mechanisms behind this treatment remain unclear. 
Additionally, contradictory evidence shows that high 
concentration ascorbic acid may lead to an increased 
expression of laminins bound to integrins, which has been 
found in patients with malignant breast cancer. This research 
will further elucidate the cellular response to high 
concentration ascorbic acid by exploring integrin switches, as 
well as possible changes in laminin expression.
HYPOTHESIS
NIH/3T3 cells treated with high ascorbic acid concentration 
may cause an integrin switch, seen by an upregulation of 
certain integrins, and a downregulation of others. 
High Concentration Ascorbic Acid May Adversely Affect Breast Cancer Metastasis and Disease Progression
METHODS
7. Data Analysis
2. Divide and apply treatment
1. Culture cells
Experimental
100 mg/mL Ascorbic 
Acid
Control
3. RNA Purification
4. Add nucleotides to build cDNA
5. Polymerase Chain Reaction (PCR)
**Applied to each treatment group**
6. Extracellular Matrix Assay
IMAGES
IMG 1: NIH/3T3 adherent control group under EVOS imaging (48 hours) 
IMG 2: NIH/3T3 adherent experimental group under EVOS imaging
• Treated with 100 mg/mL Ascorbic Acid (48 hours)
RESULTS
Fig 1: All integrins from ECM plate. This graph compares the control group 
to the experimental group with normalized results. Itga2 was 0.01 which is 
why there is no bar showing. There were two integrin genes that significantly 
downregulated: Itga2 and Itgae. The following genes were significantly 
upregulated: Itga3, Itga4, Itgam, Itgax, Itgb2, Itgb3 and Itgb4. The rest of the 
genes had little to no change. For the y axis: “Relative abundance 2(-ΔCt)”.
For the title, you don’t need to include “ECM Plate”. Maybe just: Integrin 
genes: Control vs Experimental”.
Fig 2: Genes that showed upregulation or downregulation with fold change 
normalized for control. Upregulated genes : Itga3, Itga4, Itgam, Itgax, 
Itgb2, Itgb3 and Itgb4. Downregulated genes: Itga2 (-0.01) and Itgae.
Fig 3: Basement membrane proteins linked to Breast Cancer. Fibulin and 
Laminin are upregulated by treatment of high concentration of ascorbic acid. 
Fig 4: Collagen is part of the basement membrane and is linked to Breast 
Cancer. Integrin alpha 2 and integrin beta 3 showing an integrin switch in 
high concentration of ascorbic acid treatments
Itga2
DISCUSSION
Ascorbic acid is a common cancer treatment that has been
utilized since the early 70’s. Our study intended to analyze the
efficiency of this treatment in breast cancer. What we found
after treating NIH/3T3 cells was that there was an integrin
switch which has been identified as a vital player in metastatic
diseases such as breast cancer. Additionally we analyze our
data to identify other ECM genes that may support our finding
that ascorbic acid may be a detrimental treatment option for
breast cancer.
FUTURE DIRECTION
· Repeat experiment in triplet
· Further study the relationship between ITGA2,
ITGB3, and Laminin
· Continue research on ascorbic acid treatments  and
how they affect ITGA2, ITGB3, Laminin, and breast
cancer metastasis
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